

say CVs. The high precision of the results may enable single measurements instead of multiple determination, thereby reducing costs.

The significantly lower values for ghrelin in citrate plasma may only partially (~12%) be explained by dilution with the anticoagulating liquid in the tubes ($118 \pm 15 \mu\text{L}$). The discrepancy between citrate plasma and serum was ~25%, a discrepancy that is too high for a recommendation for citrate plasma. In contrast, results for lithium-heparinate plasma were in only ~7% lower than serum results, which we consider to acceptable.

It should be kept in mind that the magnitude of the difference between values from matched sample matrices might be influenced by the assay system used, as has been shown for the determination of cardiac troponin T and I (14, 15). Our findings are based on the use of a direct RIA that is commercially available and is currently widely used for research.

As we have determined, storage of serum under cooled conditions allows stable results for up to 3 days. Storage at warm temperatures for >1 day should be avoided. This is very important when samples are transported by mail. Because no significant decrease in the ghrelin values was observed after repeated freezing and thawing, there should be no problems if sample tubes are used several times, e.g., for repeating an assay or using material after determination of other analytes.

In conclusion, ghrelin is relatively stable when stored under cooled conditions. This, as well as the fact that several sample matrices can be used as alternatives, is a good precondition for further studies on this interesting peptide hormone.

References

1. Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, et al. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. *Biochem Biophys Res Commun* 2000;275:477–80.
2. Dieguez C, Casanueva FF. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. *Eur J Endocrinol* 2000;142: 413–7.
3. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. *Trends Endocrinol Metab* 2001;12:118–22.
4. Bablok W, Passing H. Application of statistical procedures in analytical instrument testing. *J Autom Chem* 1985;7:74–9.
5. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. *J Clin Endocrinol Metab* 2001;86: 5083–6.
6. Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B. Insulin, unlike food intake, does not suppress ghrelin in human subjects. *J Clin Endocrinol Metab* 2002;87:1902.
7. Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K, et al. Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. *Hypertension* 2002;39:781–4.
8. Shiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. *J Clin Endocrinol Metab* 2002;87:240–4.
9. Gröschl M, Wagner R, Dörr HG, Blum WF, Rascher W, Dötsch J. Variability of leptin values measured from different sample matrices. *Horm Res* 2000; 54:26–31.
10. Gröschl M, Wagner R, Rauh M, Dörr HG. Stability of salivary steroids: the influences of storage, food and dental care. *Steroids* 2001;66:737–41.
11. Dabbs MJ. Salivary testosterone measurements: collecting, storing, and mailing saliva samples. *Physiol Behav* 1991;49:815–7.
12. Dattani MT, Ealey PA, Pringle PJ, Hindmarsh PC, Brook CG, Marshall NJ. An investigation into the lability of the bioactivity of human growth hormone using the ESTA bioassay. *Horm Res* 1996;46:64–73.
13. Kubasik NP, Ricotta M, Hunter T, Sine HE. Effect of duration and temperature of storage on serum analyte stability: examination of 14 selected radioimmunoassay procedures. *Clin Chem* 1982;28:164–5.
14. Stiegler H, Fischer Y, Vazquez-Jimenez JF, Graf J, Filzmaier K, Fausten B, et al. Lower cardiac troponin T and I results in heparin-plasma than in serum. *Clin Chem* 2000;46:1338–44.
15. Gerhardt W, Nordin G, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, et al. Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. *Clin Chem* 2000;46:817–21.

Biological Variation of Glycohemoglobin, Curt Rohlfing,^{1*} Hsiao-Mei Wiedmeyer,¹ Randie Little,¹ V. Lee Grotz,² Alethea Tennill,¹ Jack England,¹ Richard Madsen,¹ and David Goldstein¹ (¹ University of Missouri School of Medicine, Columbia, MO 65212; ² McNeil Specialty Products Company, New Brunswick, NJ 08903; * address correspondence to this author at: Department of Child Health, University of Missouri–Columbia, 1 Hospital Dr., M772, Columbia, MO 65212; fax 573-884-4748, e-mail RohlfingC@health.missouri.edu)

Glycohemoglobin (GHb) is a measure of long-term mean glycemia that predicts risks for the development and/or progression of diabetic complications in patients with type 1 and type 2 diabetes (1, 2). Several reports have suggested, however, that although the within-subject variation in GHb unrelated to glycemia is minimal, there is substantial between-subject variation in GHb, e.g., “low glycaters” and “high glycaters” (3–5). These reports have suggested that because of this large between-subject variation, GHb may not be useful for diabetes screening or diagnosis and that when GHb is used for routine management of patients with diabetes, different patients may require very different GHb target values to achieve the same overall glycemic status. We therefore examined the biological variation of GHb and fasting plasma glucose (FPG) in nondiabetic individuals.

Individuals without diabetes (n = 48) participated in a study of an artificial sweetener that has no effect on GHb or plasma glucose concentrations [Submission to Food and Drug Administration. McNeil Specialty Products Company food additive petition 7A3987 (Sucralose), 1987–1997]. Because the study was designed to detect minimal changes in plasma glucose concentrations, all participants were men to avoid the effects of cyclic hormonal changes on insulin (and therefore, plasma glucose) concentrations. At the prestudy screening, all individuals were healthy on the basis of a medical history, physical examination, and electrocardiography results; results of hematology and blood chemistry studies, urine examination, and measures of blood glucose control (FPG, insulin, C-peptide, and hemoglobin A_{1c}) were all within their respective reference intervals. Participants who failed a baseline oral glucose tolerance test [fasting >7.8 mmol/L (140 mg/dL), 1 h >11.1 mmol/L (200 mg/dL), and/or 2 h >7.8 mmol/L (140 mg/dL)] were excluded. Those who took medications that could affect glucose




Fig. 1. Mean, minimum, and maximum GHb for study participants. HbA_{1c}, hemoglobin A_{1c}.

metabolism or who failed a drugs-of-abuse screen, had a history of a gastrointestinal disorder, or had a history of consuming more than two alcoholic drinks per day were also excluded. Serial samples for FPG and GHb analysis were collected by venipuncture after a minimum 8-h overnight fast on a weekly basis for a total of 12 visits. Three men with <10 data points for either FPG or GHb were excluded from the analysis. The study received approval from the institutional review boards of all participating study centers, and all individuals gave informed consent before their participation.

GHb values were measured by HPLC (Primus boronate affinity; interassay CV <3%) (6). FPG values were measured by a hexokinase assay (Roche Cobas Mira; interassay CV <3%) (7). SAS software was used to perform all statistical analyses; linear regression analysis examined the correlation between initial FPG and GHb values. We estimated the between-subject (S_g^2), within-subject (S_i^2), and assay (S_a^2) components of the total variance by a nested ANOVA (8) using the SAS Proc Varcomp software; restricted maximum likelihood was the method of estimation. We calculated the within-day component of assay variance (within-day S_a^2) by combined within-run variance estimates for quality-control specimens analyzed two to five times in each analytic assay.

The mean, minimum, and maximum GHb values for each participant are shown in Fig. 1. The correlation between initial GHb and FPG values was weak but statistically significant ($r^2 = 0.102$; $P < 0.05$). Table 1 shows the estimated variance components for GHb and FPG. The S_g^2 component for GHb was much larger than the S_i^2 component. The mean GHb value was 4.9%; the between-subject SD (S_g) was 0.20% GHb ($CV_g = 4.0\%$). Thus, the between-subject mean ± 2 SD interval (95% confidence interval) was 4.5–5.3% GHb. The within-subject SD (S_i) was 0.08% GHb ($CV_i = 1.7\%$), and the between-day assay SD (between-day S_a) was 0.11% GHb ($CV_a = 2.3\%$). The S_i^2 component of variation included the within-day S_a^2 and S_i^2 because we were unable to directly separate the two components (the specimens were not analyzed in duplicate). However, the estimated within-day analytic SD (within-day S_a), based on quality-control data, was 0.07% GHb (within-day $CV_a = 1.5\%$), which indicates that

Table 1. Variance components for GHb and FPG.

Variance component	GHb, %	FPG, mmol/L
Between-subject S_g (CV_g)	0.20 (4.0%)	0.31 (5.8%)
Within-subject S_i (CV_i) ^a	0.08 (1.7%)	0.30 (5.7%)
Analytic S_a (CV_a)		
Between day	0.11 (2.3%)	0.09 (1.7%)
Within day ^b	0.07 (1.5%)	0.04 (0.8%)

^a Also includes within-day analytical variation.

^b Estimated from quality-control data.

most of the estimated CV_i was attributable to the within-day S_a^2 rather than S_i^2 .

For FPG, S_i^2 and S_g^2 were comparable. The mean FPG value was 5.3 mmol/L; the estimated S_g , S_i , and between-day S_a SDs were 0.31 mmol/L ($CV_g = 5.8\%$), 0.30 mmol/L ($CV_i = 5.7\%$), and 0.09 mmol/L (between-day $CV_a = 1.7\%$), respectively. The estimated within-day S_a , based on quality-control data, was 0.04 mmol/L (within-day $CV_a = 0.8\%$), which indicates that most of the estimated CV_i was attributable to S_i^2 .

Our data show that for GHb, S_i^2 in nondiabetic individuals is minimal. Although we were unable to obtain a precise estimate of S_i^2 separate from S_a^2 , the CV_i was likely <1%. Although the between-subject component was the largest component of the total variation in GHb, the between-subject mean ± 2 SD range in GHb for nondiabetic men was <1% GHb after accounting for S_a^2 .

A previous large-scale study has shown that GHb reliably categorizes glycemic control in nondiabetic individuals (9), and several studies have shown correlations between GHb concentrations and outcome risks in both diabetic (1,2) and nondiabetic (10,11) persons. Such findings suggest that the between-subject differences in GHb are mainly attributable to differences in mean glycemia rather than other factors.

Several factors may explain the relatively poor correlations observed between FPG and GHb values in nondiabetic individuals (3,12). Both S_i^2 and S_g^2 were higher for FPG than for GHb, and the intervals for these variables in nondiabetic individuals are relatively narrow. We also note that GHb is a more comprehensive measure of mean glycemia than FPG, as evidenced by recent studies showing that, in diabetic individuals, postmeal plasma glucose correlates better with GHb than does FPG (13,14).

Biological variation has generally been defined as "random fluctuations around a homeostatic set-point" (9,15). Several studies have examined biological variation in diabetic individuals and have concluded that there is a significant biological variation in GHb values that must be considered when test results are interpreted (5,15). It is important to note that in diabetes patients, fluctuations in GHb concentrations are not random but are "pathologic", i.e., caused by changes in mean glycemia. It is also unclear how a homeostatic setpoint can be determined for an

individual with diabetes because the setpoint itself can (and often does) change over time.

In summary, these data suggest that between-subject variation in GHb is minimal and is therefore not a major consideration when GHb is used for routine clinical care. Assay quality, however, is an important factor when interpreting GHb results (16–18), and imprecise assays may compromise the clinical utility of the test.

References

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977–86.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352:837–53.
3. Yudkin JS, Forrester RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated hemoglobin in non-diabetic subjects not related to glycaemia. *Diabetologia* 1990;33:208–15.
4. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin: implications for diabetes screening and monitoring. *Diabetes Care* 1998;21:261–4.
5. Hudson PR, Child DF, Jones H, Williams CP. Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. *Ann Clin Biochem* 1999;36:451–9.
6. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. *Clin Chem* 1994;40:1317–21.
7. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994, reference manuals and reports: manual for medical technicians and laboratory procedures used for NHANES III [CD-ROM]. Hyattsville, MD: Centers for Disease Control and Prevention, 1996.
8. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. *Crit Rev Clin Lab Sci* 1989;27:409–37.
9. Meigs JB, Nathan DM, Cupples LA, Wilson PWF, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. *J Clin Epidemiol* 1996;49:411–7.
10. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). *BMJ* 2001;322:1–6.
11. de Vegt F, Dekker JM, Ruhé HG, Stehouwer CDA, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 1999;42:926–31.
12. Simon D, Senan C, Garnier P, Saint-Paul M, Papoz L. Epidemiological features of glycated haemoglobin A1c distribution in a healthy population. *Diabetologia* 1989;32:864–9.
13. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. *Diabetes Care* 1997;20:1822–6.
14. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. *Diabetes Care* 2002;25:275–8.
15. Phillipov G, Phillips PJ. Components of total measurement error for hemoglobin A_{1c} determination [Technical Brief]. *Clin Chem* 2001;47:1851–3.
16. Larsen ML, Fraser CG, Petersen PH. A comparison of analytical goals for haemoglobin A1c assays derived using different strategies. *Ann Clin Biochem* 1991;28:272–8.
17. Watts NB. Reproducibility (precision) in alternate site testing: a clinician's perspective. *Arch Pathol Lab Med* 1995;119:914–7.
18. Coleman PG, Goodall GI, Garcia-Webb P, Williams PF, Dunlop ME. Glycohaemoglobin: a crucial measurement in modern diabetes management: progress towards standardisation and improved precision of measurement. *Med J Aust* 1997;167:96–8.

Soluble Transferrin Receptor (sTfR), Ferritin, and sTfR/Log Ferritin Index in Anemic Patients with Nonhematologic Malignancy and Chronic Inflammation, Eun Jung Lee,¹ Eun-Jee Oh,^{2,*} Yeon-Joon Park,² Hae Kyung Lee,¹ and Byung Kee Kim² (¹ Department of Clinical Pathology, College of Medicine, the Catholic University of Korea, Uijongbu St. Mary's Hospital, 65-1 Kumoh-Dong, Uijongbu-City, Kyunggi-Do 480-130, Korea; ² Department of Clinical Pathology, College of Medicine, the Catholic University of Korea, Kangnam St. Mary's Hospital, 505 Banpo-dong Seocho-ku, Seoul 137-040, Korea; * author for correspondence: fax 82-2-592-4190, e-mail ejoh@catholic.ac.kr)

The soluble transferrin receptor (sTfR) has been introduced as a promising new diagnostic tool for differentiating between iron deficiency anemia (IDA) and anemia of chronic disease (ACD) (1–3). The circulating sTfR concentration is proportional to cellular expression of the membrane-associated TfR and increases with increased cellular iron needs and cellular proliferation (4). Furthermore, because serum ferritin reflects the storage iron compartment and sTfR reflects the functional iron compartment, the sTfR/log ferritin index (sTfR-F index), based on these two values, has been suggested as a good estimate of body iron compared with the sTfR/ferritin ratio (5). However, whether they could be useful in evaluating the iron deficiency in various malignancies has not been reported. In addition, some data have demonstrated that sTfR offers little advantage over conventional laboratory indicators of iron status (6) and might not assess the iron status of patients with ACD. A potential explanation for these differences may be the ACD patient population studied. Because several studies of patients with solid malignancies have reported that the erythropoietin concentrations are inappropriate for the degree of anemia (7) and chemotherapy-induced bone marrow (BM) suppression may also decrease sTfR concentration, the sTfR concentrations in the ACD population may depend on the proportion of patients with malignancy in the study group.

In the present study, we assessed the diagnostic performance of sTfR, ferritin, and sTfR-F index for detecting iron depletion in several groups of patients (IDA, chronic inflammation or infection, and nonhematologic malignancy) according to the guidelines (8). The diagnostic classification of all patients was based on an examination of the BM iron stain as the gold standard for iron depletion.

The patient population consisted of 120 (58 men and 62 women; age range, 21–85 years; mean, 54 years) anemic adult patients who underwent a BM examination for anemia study and 81 nonanemic controls. The 120 anemic patients were divided into five populations on the basis of the BM examination and clinical data: IDA (n = 31), which included patients who had no stainable iron in the BM because of an uncomplicated iron deficiency (i.e., simple blood loss); I-IDA (n = 15), which included patients who had chronic inflammatory disease (chronic